Aim & Scope
Clinical Trials and Bioavailability Research (ISSN: 2836-5836) is an international, Open Access publisher of peer-reviewed journals encompassing a broad spectrum of scientific research and technological disciplines.
Clinical Trials and Bioavailability Research (ISSN: 2836-5836) is originated with a rigid commitment of serving the scientific and research community by inviting innovations and a vision to encourage the existing scientists, experts and young scientists to enlighten the common society, encompassing a broad spectrum of scientific research and technological disciplines.
Clinical Trials and Bioavailability Research (ISSN: 2836-5836) is an open access, single-blinded, peer-reviewed medical journal that publishes original research articles, review papers, clinical studies, case reports, editorials, perspectives, etc. It seeks support from individuals, institutes, libraries, universities, funding agencies, and others.
Clinical Trials and Bioavailability Research (ISSN: 2836-5836) deals with the disorders and complications that are related to drug efficacy, pharmacokinetics, bioavailability, clinical trial outcomes, and therapeutic interventions.
The current research in Clinical Trials and Bioavailability Research (ISSN: 2836-5836) involves in the development of new techniques to minimize these ailments and provides knowledge for researchers, practitioners, and even common people.
Clinical Trials and Bioavailability Research (ISSN: 2836-5836) accepts the articles in the fields of: Clinical Trials, Randomized Controlled Trials (RCTs), Phase I, II, III, IV Clinical Trials, Adaptive Clinical Trials, Double-Blind Studies, Placebo-Controlled Trials, Crossover Trials, Parallel Group Studies, Multicenter Trials, Observational Studies, Clinical Trial Design, Good Clinical Practice (GCP), Ethical Considerations in Clinical Trials, Informed Consent in Clinical Research, Institutional Review Board (IRB), Regulatory Affairs in Clinical Trials, FDA/EMA Clinical Trial Guidelines, Investigational New Drug (IND) Application, Clinical Endpoint Determination, Pharmacovigilance & Drug Safety, Post-Marketing Surveillance, Bioavailability & Bioequivalence, Pharmacokinetics (PK), Pharmacodynamics (PD), Drug Absorption & Metabolism, First-Pass Metabolism, Cmax (Maximum Plasma Concentration), Tmax (Time to Maximum Concentration), Area Under the Curve (AUC), Drug Distribution & Clearance, Bioequivalence Studies, In Vitro-In Vivo Correlation (IVIVC), Biopharmaceutics Classification System (BCS), Personalized Medicine in Clinical Trials, AI & Machine Learning in Clinical Research, Virtual & Decentralized Clinical Trials, Wearable Technology in Clinical Trials, Data Integrity & Transparency in Clinical Trials.
Authors can contribute their valuable submission through online and/or to info@mediresonline.org
Clinical Trials: are structured research studies that evaluate the safety, efficacy, and side effects of new drugs, treatments, or medical interventions in humans. They are conducted in phases to ensure rigorous testing before approval. Clinical trials provide evidence-based data to guide medical practice and improve patient care.
Placebo-Controlled Trials: are clinical studies in which the effects of an experimental treatment are compared with a placebo, an inactive substance. This design helps determine the true efficacy and safety of the treatment. It minimizes bias and ensures reliable, scientifically valid results.
Crossover Trials: are clinical studies in which participants receive multiple interventions sequentially, with a washout period in between. Each participant acts as their own control, allowing direct comparison of treatments. This design increases study efficiency and reduces variability in results.
Informed Consent in Clinical Research: is the process of providing participants with complete information about a study, including its purpose, procedures, risks, and benefits. Participants voluntarily agree to take part, understanding their rights and the option to withdraw at any time. It ensures ethical conduct and protects participant autonomy.
Regulatory Affairs in Clinical Trials: involves ensuring that studies comply with local and international laws, guidelines, and ethical standards. It includes submitting trial protocols for approval, monitoring compliance, and maintaining documentation. Regulatory affairs safeguard participant safety and ensure the validity and credibility of clinical research.
Pharmacokinetics (PK): is the study of how a drug is absorbed, distributed, metabolized, and excreted by the body. It helps determine the appropriate dosage, frequency, and route of administration. Understanding PK is essential for optimizing drug efficacy and minimizing side effects.
Drug Distribution & Clearance: Describe how a drug moves through the body and is eliminated. Distribution refers to the dispersion of the drug to tissues and organs, influenced by blood flow, protein binding, and tissue permeability. Clearance is the rate at which the drug is removed, primarily via the liver and kidneys, determining its duration and dosing regimen.
Personalized Medicine in Clinical Trials: involves tailoring treatments based on a participant’s genetic, molecular, or clinical profile. It aims to improve efficacy and reduce adverse effects by selecting therapies most likely to benefit each individual. Incorporating personalized approaches enhances trial outcomes and advances precision healthcare.
Wearable Technology in Clinical Trials: refers to devices like smartwatches, sensors, or biosensors used to continuously monitor participants’ physiological or behavioral data. They provide real-time insights on treatment effects, adherence, and safety. Wearables enhance data accuracy, patient engagement, and the efficiency of clinical research.
Investigational New Drug (IND) Application: a regulatory submission to authorities, such as the FDA, seeking permission to begin clinical trials of a new drug in humans. It includes preclinical data, proposed study protocols, and safety information. Approval ensures that trials are conducted safely and ethically.
